Singapore markets open in 1 hour 10 minutes

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.15-0.13 (-2.07%)
At close: 04:00PM EST
6.03 -0.12 (-1.95%)
After hours: 05:20PM EST

Repare Therapeutics Inc.

7210 Frederick-Banting
Suite 100
St-Laurent, QC H4S 2A1
857 412 7018

Full-time employees180

Key executives

NameTitlePayExercisedYear born
Mr. Lloyd Mitchell SegalPresident, CEO & Director913.39kN/A1964
Dr. Michael Zinda Ph.D.Executive VP & Chief Scientific Officer641.53kN/A1971
Dr. Maria Koehler M.D., Ph.D.Executive VP & Chief Medical Officer682.8kN/A1957
Dr. Daniel Durocher Ph.D.Co-FounderN/AN/AN/A
Dr. Frank Sicheri Ph.D.Co-FounderN/AN/AN/A
Dr. Agnel Sfeir Ph.D.Co-FounderN/AN/AN/A
Mr. Steve ForteExecutive VP & CFO608.52kN/A1979
Mr. Daniel BelangerExecutive Vice President of Human ResourceN/AN/AN/A
Mr. Cameron BlackExecutive Vice President of DiscoveryN/AN/AN/A
Dr. Kim A. Seth Ph.D.Executive VP & Chief Business OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

Corporate governance

Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.